| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Atherosclerotic plaque disruption does not always result in acute symptomatic events. Therefore, the thrombogenicity of the atherosclerotic plaques is a critical factor in the development of atherothrombosis. However, little is known about determinants of the plaque thrombogenicity. We found that metabolite levels of glycolysis increase in macrophage-rich atherosclerotic arteries, and that arterial glucose uptake reflects vascular thrombogenicity, which might be partly explained by metabolic adaptation and enhanced procoagulant activity in a hypoxic microenvironment. Expression of hexokinase II, a glycolytic enxyme upregulated by hypoxia, in the atherosclerotic plaques correlated with human coronary thrombus size. The novel findings will allow the detection of high-risk plaques and the development of atherosclerosis therapies.
|
